Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis | Zendy

Juan Macı́as | Zendy; Francisco Orihuela | Zendy; A. Rivero | Zendy; Pompeyo Viciana | Zendy; Manuel Márquez | Zendy; Joaquín Portilla | Zendy; María Rios | Zendy; Luís MuñozBellvis | Zendy; Juan Pasquau | Zendy; Manuel Castaño | Zendy; Laila AbdelKader Martín | Zendy; Juan A. Pineda | Zendy

Open Access

Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis

Author(s) -

Juan Macı́as,

Francisco Orihuela,

A. Rivero,

Pompeyo Viciana,

Manuel Márquez,

Joaquín Portilla,

María Rios,

Luís MuñozBellvis,

Juan Pasquau,

Manuel Castaño,

Laila AbdelKader Martín,

Juan A. Pineda

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn429

Subject(s) - ritonavir , hepatitis a virus , medicine , virology , hepatitis c virus , hepatitis c , human immunodeficiency virus (hiv) , microbiology and biotechnology , virus , antiretroviral therapy , biology , viral load

The aim of this study was to evaluate the incidence and risk factors of severe liver events among HIV-infected patients treated with drug combinations including tipranavir boosted with ritonavir (TPV/r).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research